Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications

Stem Cell Reports

Volumn 8, Issue 5, 2017, Pages 1190-1201

  Fung, Moses ^a   Yuan, Yan ^a   Atkins, Harold ^b   Shi, Qian ^a   Bubela, Tania ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

clinical translation; clinical trial; clinical trial publication; clinical trial registry; stem cell; stem cell tourism

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); EMBASE; HAZARD RATIO; HEALTH CARE; HUMAN; MEDLINE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; PUBLISHING; QUALITATIVE ANALYSIS; QUALITY CONTROL; REGENERATIVE MEDICINE; REGISTRATION; SAFETY; STEM CELL; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; TRANSLATIONAL RESEARCH; ETHICS; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA;

CLINICAL TRIALS AS TOPIC; HUMANS; PERIODICALS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION;

EID: 85017431093     PISSN: 22136711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.stemcr.2017.03.013     Document Type: Article

References (63)

1. Aging Analytics Agency, Investing in Regenerative Medicine: Technology Analysis and Market Outlook. 2014, LRMN Report No. 1.
2. Anderson, J.A., Kimmelman, J., Are phase 1 trials therapeutic? Risk, ethics and division of labor. Bioethics 28 (2014), 138–146.
3. Berkowitz, A.L., Miller, M.B., Mir, S.A., Cagney, D., Chavakula, V., Guleria, I., Aizer, A., Ligon, K.L., Chi, J.H., Glioproliferative lesion of the spinal cord as a complication of “Stem-Cell Tourism”. N. Engl. J. Med. 375 (2016), 196–198.
4. Blumle, A., Meerpohl, J.J., Schumacher, M., von Elm, E., Fate of clinical research studies after ethical approval—follow-up of study protocols until publication. PLoS One, 9, 2014, e87184.
5. Bubela, T., Li, M.D., Hafez, M., Bieber, M., Atkins, H., Is belief larger than fact: expectations, optimism and reality for translational stem cell research. BMC Med., 10, 2012, 133.
6. Camacho, L.H., Bacik, J., Cheung, A., Spriggs, D.R., Presentation and subsequent publication rates of phase I oncology clinical trials. Cancer 104 (2005), 1497–1504.
7. Caulfield, T., Scott, C., Hyun, I., Lovell-Badge, R., Kato, K., Zarzeczny, A., Stem cell research policy and iPS cells. Nat. Methods 7 (2010), 28–33.
8. Caulfield, T., Sipp, D., Murry, C.E., Daley, G.Q., Kimmelman, J., Confronting stem cell hype. Science 352 (2016), 776–777.
9. Chapman, A.R., Scala, C.C., Evaluating the first-in-human clinical trial of a human embryonic stem cell-based therapy. Kennedy Inst. Ethics J. 22 (2012), 243–261.
10. Charo, R.A., On the road (to a cure?)—stem-cell tourism and lessons for gene editing. N. Engl. J. Med. 374 (2016), 901–903.
11. Chen, R., Desai, N.R., Ross, J.S., Zhang, W., Chau, K.H., Wayda, B., Murugiah, K., Lu, D.Y., Mittal, A., Krumholz, H.M., Hines, H.H. Jr., Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ, 352, 2016, i637.
12. Committee for Medicinal Products for Human Use, Guideline on Strategies to Identify and Mitigate Risks for First-in-human Clinical Trials with Investigational Medicinal Products. 2007, European Medicines Agency Document No. EMEA/CHMP/SWP/28367/07.
13. Daley, G.Q., Hyun, I., Apperley, J.F., Barker, R.A., Benvenisty, N., Bredenoord, A.L., Breuer, C.K., Caulfield, T., Cedars, M.I., Frey-Vasconcells, J., et al. Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines. Stem Cell Rep. 6 (2016), 787–797.
14. Decullier, E., Chan, A.W., Chapuis, F., Inadequate dissemination of phase I trials: a retrospective cohort study. PLoS. Med., 6, 2009, e1000034.
15. Dlouhy, B.J., Awe, O., Rao, R.C., Kirby, P.A., Hitchon, P.W., Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient: case report. J. Neurosurg. Spine 21 (2014), 618–622.
16. Dwan, K., Altman, D.G., Clarke, M., Gamble, C., Higgins, J.P., Sterne, J.A., Williamson, P.R., Kirkham, J.J., Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. PLoS Med., 11, 2014, e1001666.
17. Galipeau, J., The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 15 (2013), 2–8.
18. Goldring, C.E., Duffy, P.A., Benvenisty, N., Andrews, P.W., Ben-David, U., Eakins, R., French, N., Hanley, N.A., Kelly, L., Kitteringham, N.R., et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell 8 (2011), 618–628.
19. Hakala, A., Kimmelman, J., Carlisle, B., Freeman, G., Fergusson, D., Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials. BMJ, 350, 2015, h1116.
20. Health Canada, Guidance for Industry: Structure and Content of Clinical Study Reports ICH Topic E3. 1996, Health Canada Catalogue No. H42–2/67-10-1996E.
21. Heathman, T.R., Nienow, A.W., McCall, M.J., Coopman, K., Kara, B., Hewitt, C.J., The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen. Med. 10 (2015), 49–64.
22. Hopewell, S., Loudon, K., Clarke, M.J., Oxman, A.D., Dickersin, K., Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst. Rev., 2009 MR000006.
23. Huić, M., Marušić, M., Marušić, A., Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy. PLoS One, 6, 2011, e25258.
24. Huser, V., Cimino, J.J., Linking ClinicalTrials.gov and PubMed to track results of interventional human clinical trials. PLoS One, 8, 2013, e68409.
25. ICH Expert Working Group No. E3, ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports. 1995, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
26. International Society for Stem Cell Research, The ISSCR Patient Handbook on Stem Cell Therapies: Appendix 1 of the Guidelines for the Clinical Translation of Stem Cells. 2008, International Society for Stem Cell Research.
27. International Society for Stem Cell Research, ISSCR Guidelines for the Clinical Translation of Stem Cells. In Current Protocols in Stem Cell Biology. 2009, John Wiley & Sons, Inc. Appendix 1B.
28. International Society for Stem Cell Research, Guidelines for Stem Cell Research and Clinical Translation. 2016, International Society for Stem Cell Research.
29. Isasi, R.M., Registration of Stem Cell-Based Clinical Trials: A Scientific and Ethical Imperative. 2009, Genetics Policy Institute, World Stem Cell Report No. 501c3.
30. Jones, C.W., Handler, L., Crowell, K.E., Keil, L.G., Weaver, M.A., Platts-Mills, T.F., Non-publication of large randomized clinical trials: cross sectional analysis. BMJ, 347, 2013, f6104.
31. Jüni, P., Altman, D.G., Egger, M., Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323 (2001), 42–46.
32. Kimmelman, J., The secret realm of phase I trials in healthy volunteers. BMJ, 350, 2015, h3444.
33. Kimmelman, J., Heslop, H.E., Sugarman, J., Studer, L., Benvenisty, N., Caulfield, T., Hyun, I., Murry, C.E., Sipp, D., Daley, G.Q., New ISSCR guidelines: clinical translation of stem cell research. Lancet 387 (2016), 1979–1981.
34. Kimmelman, J., Hyun, I., Benvenisty, N., Caulfield, T., Heslop, H.E., Murry, C.E., Sipp, D., Studer, L., Sugarman, J., Daley, G.Q., Policy: global standards for stem-cell research. Nature 533 (2016), 311–313.
35. Kuriyan, A.E., Thomas, A., Townsend, J.H., Rodriguez, Z., Pandya, H.K., Leonard, R.E. II, Parrott, M.B., Rosenfeld, P.J., Flynn, H.W., Goldberg, J.L., Vision loss after intravitreal injection of autologous “stem cells” for AMD. N. Engl. J. Med. 376 (2017), 1047–1053.
36. Laine, C., Horton, R., DeAngelis, C.D., Drazen, J.M., Frizelle, F.A., Godlee, F., Haug, C., Hébert, P.C., Kotzin, S., Marusic, A., et al. Clinical trial registration–Looking back and moving ahead. N. Engl. J. Med. 356 (2007), 2734–2736.
37. Lau, D., Ogbogu, U., Taylor, B., Stafinski, T., Menon, D., Caulfield, T., Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 3 (2008), 591–594.
38. Levine, A.D., Insights from patients’ blogs and the need for systematic data on stem cell tourism. Am. J. Bioeth. 10 (2010), 28–29.
39. Li, M.D., Atkins, H., Bubela, T., The global landscape of stem cell clinical trials. Regen. Med. 9 (2014), 27–39.
40. Martin, P.J., Uberti, J.P., Soiffer, R.J., Klingemann, H., Waller, E.K., Daly, A.S., Herrmann, R.P., Kebriaei, P., Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol. Blood Marrow Transplant 16 (2010), S169–S170.
41. Master, Z., Resnik, D.B., Stem-cell tourism and scientific responsibility: stem-cell researchers are in a unique position to curb the problem of stem-cell tourism. EMBO Rep. 12 (2011), 992–995.
42. Master, Z., Robertson, K., Frederick, D., Rachul, C., Caulfield, T., Stem cell tourism and public education: the missing elements. Cell Stem Cell 15 (2014), 267–270.
43. Moher, D., Hopewell, S., Schulz, K.F., Montori, V., Gøtzsche, P.C., Devereaux, P.J., Elbourne, D., Egger, M., Altman, D.G., Consolidated Standards of Reporting Trials Group, CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J. Clin. Epidemiol. 63 (2010), e1–37.
44. National Institutes of Health, About the Results Database. 2015, National Institutes of Health Available at: http://clinicaltrials.gov/ct2/about-site/results.
45. Ogbogu, U., Rachul, C., Caulfield, T., Reassessing direct-to-consumer portrayals of unproven stem cell therapies: is it getting better?. Regen. Med. 8 (2013), 361–369.
46. Prayle, A.P., Hurley, M.N., Smyth, A.R., Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ, 344, 2012, d7373.
47. R Development Core Team, A Language and Environment for Statistical Computing [software]. 2008, R Foundation for Statistical Computing http://www.R-project.org [cited 30 May 2016].
48. Rettig, R.A., Jacobson, P.D., Farqhuar, C.M., Aubry, W.M., False Hope: Bone Marrow Transplantation for Breast Cancer. 2007, Oxford University Press.
49. Ross, J.S., Tse, T., Zarin, D.A., Xu, H., Zhou, L., Krumholz, H.M., Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ, 344, 2012, d7292.
50. Schulz, K.F., Altman, D.G., Moher, D., CONSORT Group, CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ, 340, 2010, 332.
51. Sipp, D., Conditional approval: Japan lowers the bar for regenerative medicine products. Cell Stem Cell 16 (2015), 353–356.
52. Sipp, D., Turner, L., U.S. regulation of stem cells as medical products. Science 338 (2012), 1296–1297.
53. Suñé, P., Suñé, J.M., Montoro, J.B., Positive outcomes influence the rate and time to publication, but not the impact factor of publications of clinical trial results. PLoS One, 8, 2013, e54583.
54. Trounson, A., McDonald, C., Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17 (2015), 11–22.
55. Turner, L., Knoepfler, P., Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell 19 (2016), 154–157.
56. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Guidance for Industry: E3 Structure and Content of Clinical Study Reports—Questions and Answers (R1). 2013, Food and Drug Administration.
57. Vawdrey, D.K., Hripcsak, G., Publication bias in clinical trials of electronic health records. J. Biomed. Inform. 46 (2013), 139–141.
58. Viergever, R.F., Ghersi, D., The quality of registration of clinical trials. PLoS One, 6, 2011, e14701.
59. von Elm, E., Röllin, A., Blümle, A., Huwiler, K., Witschi, M., Egger, M., Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee. Swiss Med. Wkly. 138 (2008), 197–203.
60. von Tigerstrom, B.J., The challenges of regulating stem cell-based products. Trends Biotechnol. 26 (2008), 653–658.
61. World Health Organization, International Clinical Trials Registry Platform. 2016, World Health Organization Available at: http://www.who.int/ictrp/network/trds/en/.
62. Zarin, D.A., Williams, R.J., Bergeris, A., Dobbins, H., Ide, N.C., Loane, R.F., Robbins, A., Tse, T., ClinicalTrials.gov and Related Projects: Improving Access to Information about Clinical Studies. 2013, The Lister Hill National Center for Biomedical Communications Report No. TR-2013-001.
63. Ziegler, A., Kastner, C., Blettner, M., The generalised estimating equations: an annotated bibliography. Biom. Z. 40 (1998), 115–139.